[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506867":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":26,"locations":32,"responsibleParty":50,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Institute of Tropical Medicine, Belgium","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"mpox patients",null,"mpox cohort diagnosed and confirmed by PCR at the Institute of Tropical Medicine (ITM) in Antwerp during the recent mpox outbreak May-October 2022, 95 consented patients for follow-up",{"label":13,"type":10,"description":14,"interventionNames":10},"Smallpox vaccine recipients","sub-group 1: 100 participants routinely vaccinated with two subcutaneous 3rd generation smallpox vaccines sub-group 2: 100 participants routinely vaccinated with two intradermal 3rd generation smallpox vaccines",{"label":16,"type":10,"description":17,"interventionNames":10},"Healthy controls","50 controls recruited during HIV-PrEP consultation (no former mpox infection, no smallpox vaccination)",[19,23],{"name":20,"affiliation":21,"role":22},"Nicole Berens-Riha, PhD","Institute of Tropical Medicine","PRINCIPAL_INVESTIGATOR",{"name":24,"affiliation":21,"role":25},"Laurens Liesenborghs, PhD","STUDY_DIRECTOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Study Coordinator","CONTACT","+32(0)33455672","bsmekens@itg.be",[33],{"facility":21,"status":34,"city":35,"state":10,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Antwerp","2000","Belgium","BE",{"type":40,"coordinates":41},"Point",[42,43],4.40026,51.22047,{"lat":43,"lon":42},[46],{"name":47,"role":29,"phone":48,"phoneExt":10,"email":49},"Yven Van Herrewege","+32(0)33455557","yvanherrewege@itg.be",{"type":51,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100506867","prospective-study-for-the-follow-up-of-human-monkeypox-cases-and-smallpox-vaccinees-at-risk-100506867",false,"NCT05879965","Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk","Prospective On-site and Questionnaire Study for the FOLLOW-UP of Mpox Cohort at ITM PLUS Evaluation of the Longevity of B- and T-cell Immune Responses in Former Mpox Patients and Vaccine Recipients","POQS-FU PLUS","Mpox patients for immunological study\n\nInclusion criteria\n\n* PCR-confirmed mpox infection since May 2022\n* ≥18 years\n* Willingness to provide written informed consent\n* Willingness to follow the study schedule\n\nExclusion criteria\n\n* Any vaccination 2 weeks before or after the visits (4 weeks for life-vaccines)\n* Any immune-compromising drugs or diseases (treated and controlled HIV-infection is no exclusion criteria)\n* Any mpox reinfection since study start\n\nSmallpox vaccinees for immunological study\n\nInclusion criteria\n\n* At least two smallpox vaccinations.\n* ≥18 years\n* Willingness to provide written informed consent\n* Willingness to follow the study schedule\n\nExclusion criteria\n\n* Any vaccination 2 weeks before or after the visits (4 weeks for life-vaccines)\n* Any immune-compromising drugs or diseases (treated and controlled HIV-infection is no exclusion criteria)\n* Any mpox infection in the past\n\nHIV-Prep patients\n\nInclusion criteria\n\n* On HIV-PrEP and a patient from ITM\n* ≥18 years\n* Willingness to provide written informed consent\n* Willingness to follow the study schedule\n\nExclusion criteria\n\n* Born before 1976\n* Any documented or remembered smallpox vaccination or typical scar for a smallpox vaccination\n* Any vaccination 2 weeks before or after the visits (4 weeks for life-vaccines)\n* Any immune-compromising drugs or diseases\n* Any mpox infection in the past","ALL","18 Years",{"count":63,"type":64},345,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to describe possible physical and psychological sequelae after an mpox infection and to evaluate the longevity of B- and T-cell immune responses in former mpox patients and vaccine recipients.\n\nThe main questions it aims to answer are:\n\n* Are there any physical or pschological sequelae after mpox infection?\n* Is the humoral and\u002For cellular immune response to MPOX (or vaccinia) virus) durable?\n* Do the patients develop strong local immunity in comparison to systemic immunity?\n* How long is the virus still detectable in semen, saliva or the ano-rectal region?\n\nParticipants will answer a questionnaire, samples with blood, saliva and semen as well as anal swabs will be collected. Follow-up visits 8, 16 and 24, 36, 48, and 60 months after infection or vaccination are planned.\n\nA healthy control group will be recruited in our HIV-PrEP clinic.",[68],"Monkeypox",[70,71,72,73,74],"mpox","immunology","mucosal immunity","sequelae","smallpox vaccination","2026-03-17",{"date":77,"type":78},"2026-03-19","ACTUAL",{"date":80,"type":78},"2022-10-06",{"date":82,"type":64},"2028-06",{"name":5,"class":6},1]